Fresh From the Bench: Latest Precedential Patent Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Mobile Acuity Ltd. v. Blippar Ltd., Appeal No. 2022-2216 (Fed. Cir. Aug. 6, 2024)
In its only precedential patent opinion last week, the Federal Circuit confirmed the invalidity of all claims of two asserted patents as abstract under Section 101. Although the Section 101 analysis follows a long line of cases, the procedural aspects of this case sounded a cautionary note to patent plaintiffs and their counsel about the practice of using representative claims in litigation.
Mobile Acuity sued Blippar for infringing two patents titled “Storing Information for Access Using a Captured Image.” In general, the patents disclosed methods and devices relating to “storing information so that it can be accessed using a captured image.” In its complaint, Mobile Acuity alleged that Blippar had infringed “one or more claims” of the patents. The Court issued a scheduling order, under which the parties were free to amend the pleadings up to a date certain.
Editors:
Nika Aldrich, IP Litigation Group Leader, Schwabe, Williamson & Wyatt, P.C.
Jason A. Wrubleski, Shareholder
More insights
PTAB in 2026: What Practitioners Are Getting Wrong
Institution rates have moved, but the reasoning behind them has moved further. The number most petitions still cite is the headline institution rate — and it has not been the operative number for two years. The two stage problem A petition now has to…
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…